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Received September 7, 2010; accepted February 17, 2011AbstractBackground: A novel influenza H1N1 began in March 2009, rapidly spread, and then became a pandemic outbreak. Diagnosis by polymerase
chain reaction result was not always available because of a surge in workload and therefore clinical diagnosis became important. However,
clinical differences between the patients infected by the novel H1N1 virus and those infected by the influenza-like non-novel H1N1 have not
been reported. This study was conducted to compare the demographic background, clinical manifestations, and laboratory findings between
novel H1N1 influenza infections and other non-novel H1N1 infections.
Methods: At an early stage of H1N1 spread, cases presenting with influenza-like symptom and travel or contact history were quarantined into
infection disease-designated hospitals in Taiwan. Data on consecutive patients under investigation for infection with novel influenza A (H1N1)
were collected between April 29 and June 19, 2009. The data set consisted of clinical manifestations, plain chest radiography, hematological
results, and biochemical findings. Testing of nasopharyngeal swab samples by reverse transcription polymerase chain reaction was used to detect
H1N1.
Results: Overall, 166 cases were collected. Among these individuals, there were 14 confirmed H1N1 cases. The clinical manifestations of the
H1N1 cases included fever in 13 patients (92.9%), followed by cough, rhinorrhea, a sore throat, myalgia, headache, malaise, abdominal
tenderness, and diarrhea. Leukopenia was present in nine patients (64.2%) and lymphocytopenia was present in five (35.7%). The duration of
virus shedding was 7.0  1.8 days. When compared with the non-H1N1 cases by multiple logistic regression analysis, cases infected by the
novel H1N1 virus were more likely to be younger than 20 years [Odds ratio (OR) ¼ 27.7, 95% confidence interval (CI) ¼ 1.3e597.8,
p ¼ 0.034), have traveled from the US (OR ¼ 14.5, 95% CI ¼ 2.1e101.4, p ¼ 0.007) or Thailand (OR ¼ 56.7, 95% CI ¼ 4.6e700.6, p ¼ 0.002)
and to have presented with myalgia (OR ¼ 8.5, 95% CI ¼ 1.4e52.0, p ¼ 0.021) or leukopenia (OR ¼ 17.4, 95% CI ¼ 3.4e90.5, p ¼ 0.001).
Conclusion: When a patient presents with influenza-like acute febrile respiratory illness symptoms and is young in age, has a travel history
involving an affected area, and is suffering from myalgia or leukopenia, physicians should be alerted to the possibility of novel H1N1 virus
infection.
Copyright  2011 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Novel influenza A (H1N1) is a new triple-reassortant
virus,1e3 which contains genes from human, swine, and
avian influenza A viruses; this virus first caused illness in
Mexico4 and the United States5 during March and April of
2009. It was quickly determined that the virus was spreadinghinese Medical Association. All rights reserved.
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country to country. By June 11, 2009, nearly 30,000 confirmed
cases had been reported in 74 countries. As a result, the World
health organization (WHO) decided to raise the level of the
influenza pandemic alert from Phase 5 to Phase 6.6 By August
1, 2010, it was estimated that over 214 countries and overseas
territories or communities had reported laboratory confirmed
cases of pandemic influenza H1N1 2009 and infection had
caused at least 18,449 deaths.7
On April 27, 2008, the Department of Health in Taiwan, in
conjunction with the Center for Disease Control and Preven-
tion, Taiwan (CDC, Taiwan), began implementing measures to
limit the spread of the novel H1N1 influenza in Taiwan.8
Airport checkpoints, where temperature checks were carried
out and health declarations filled in, were set up to screen
people coming into Taiwan. Travelers arriving from abroad
with a fever or flu-like symptoms (cough, sore throat etc.)
were asked to wear N-95 masks and were sent immediately to
a designated hospital for quarantine and further diagnosis.
Travelers who did not have a fever or symptom were asked to
check their body temperature each morning and night for
7 days. If they developed fever or influenza-like symptoms
during this time, they were asked to wear N-95 masks and
report to a designated hospital for further diagnosis and
quarantine immediately. Individuals who had been in contact
with those quarantined cases and developed fever or influenza-
like symptoms were also quarantined.
In this study, we analyzed the characteristics, initial clinical
symptoms, physical examination results, and laboratory find-
ings of patients sent to the designated infectious disease
control hospital, the Taipei City Hospital, Heping branch, for
quarantine procedures.
2. Methods
Between April 29 and June 19, 2009, 166 consecutive cases
were quarantined and investigated for novel influenza
A (H1N1) infection at the Heping branch of Taipei City
Hospital. After a physician’s diagnosis that the individual was
a “person under investigation”, the cases were quarantined in
a negative-pressure isolation facility at the Heping branch. The
definition of a “person under investigation” was based on the
guidance established by the CDC, Taiwan, including
the clinical criteria for an acute febrile respiratory illness, the
clinical criteria for an influenza-like-illness {defined as fever
[temperature of 100F (37.8C) or greater] and a cough and/or
a sore throat in the absence of a known cause other than
influenza}, or pneumonia; in addition there were also epide-
miological criteria including close contact with or travel to
area with confirmed or probable cases of H1N1.9 Baseline and
daily clinical data, including demographical information,
travel history, exposure history, symptoms and signs, comor-
bidities, and laboratory information were obtained during the
patients’ quarantine in the hospital. The initial investigation
consisted of a local examination of the ears, nose, and throat,
palpation of the bilateral nuchal areas, a complete blood panel
including differential counts, serum biochemical studiesincluding blood sugar, renal and liver functions, a C-reactive
protein assay, and plain chest radiography. Analysis of each
patient’s nasopharyngeal swab samples by reverse transcrip-
tion polymerase chain reaction (RT-PCR) was conducted by
a laboratory at the CDC, Taiwan. Molecular tests were carried
out for influenza A/B and subtyping tests were used to identify
pandemic H1N1, seasonal H3N2 and seasonal H1N1. Detec-
tion of other respiratory pathogens was not performed. All
patients were placed in negative-pressure isolation facilities
initially, and treated with oseltamivir thereafter (orally twice
a day for 5 days in a dosage based on body weight, according
to the manufacturer’s recommendations). During quarantine,
serial routine examinations, such as body temperature, blood
pressure, respiratory rate, heart rate, and O2 saturation were
recorded. Among the 166 cases, 14 patients were confirmed to
be cases of human infection with novel influenza A (H1N1).
The confirmed cases were defined as any case with a labora-
tory confirmation by RT-PCR carried out at the CDC, Taiwan
using a rapid SYBR green I RT-PCR method.10 The primers
used for pandemic influenza strain H1N1 detection in the SYBR
green I assay were designed by the Taiwan CDC and based on
the sequence of strain A/California/04/2009. The primers
were SWH1LF (50-ATTACTGGACACTAGTAGAGC-30) and
SWH1LR (50-GCATTTCTTTCCATTGCGAA-30), which
amplify a 97-bp fragment within the hemagglutinin gene. The
assay was performed using the Roche LightCycler and
LightCycler RNA master SYBR green I kit. The detection
limit of the assay was at least 10 copies/mL of the hemag-
glutinin gene. The high sensitivity of fluorogenic 50 nuclease
assays means that special precautions must be taken to avoid
false-positive amplifications. A false-negative result may
occur if inadequate numbers of organisms are present in the
specimen because of improper collection or poor transport/
handling; furthermore, such a result may occur if an excess of
DNA/RNA template is present in the reaction mix.
RT-PCR was also used to analyze serial sampling of the
nasopharynx to assess viral shedding by the confirmed cases
during their quarantine. A second nasopharyngeal sampling
for RT-PCR was decided on by the doctor after the symptoms
and signs had subsided. If the sample was positive, another
sampling was done again 48 hours later. The criteria for
discharge from quarantine were two successive negative PCR
results for influenza from nasopharyngeal swabs taken at least
24 hours apart. This study was approved by the institutional
review board of Taipei City Hospital.
3. Statistical analysis
The analysis of the data was carried out using a statistical
software package (SPSS, version 13.0; SPSS; Chicago, IL).
Descriptive statistics are presented as numbers of cases,
percentages, and means with standard deviation. Fisher’s exact
test was used to evaluate the significance of any differences.
Furthermore to the descriptive analyses, multiple logistic
regression analysis using the stepwise method was used to
evaluate the risk indicators for being infected by novel H1N1
influenza virus.
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outbreak strain of novel influenza H1N1 virus were identified
by RT-PCR (Table 1); one was a Thai national (patient No. 6)
and all the others were Taiwan citizens. All the confirmed
cases were travelers except for patient No. 11. Seven cases
(50%) reported that they had traveled from the US and four
cases (35.7%) reported that they had traveled from Thailand,
all within 7 days before the onset of illness. One confirmed
case had a history of travel to Central America. The one
indigenous case was found to have had close contact with
patient No. 10, who was a family member. Furthermore,
patients No. 8, 9, and 12 were members of the same family,
which was a different family from that of patient No. 10. None
of the 166 patient case histories indicated a disease that might
cause an increase or decrease in the patients’ white cells or
thrombocytes, such as a bone marrow disease or the use of
specific medication (e.g. corticosteroid, lithium, or beta-
adrenoceptor agonists).ti
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s.The age of patients with confirmed novel H1N1 infection
ranged from 8 years to 57 years (mean age: 23.6  12.2 years)
(Table 1). A total of 42.9% of patients were of the ages 0e20
years, and only 7.1% of patients were 41 years old (Table 2).
Seven were men and seven were women. The most common
symptoms were fever, cough, and rhinorrhea, as shown in
Table 1. No cases were reported to have chills, dizziness, or
remarkable gastrointestinal symptoms, such as diarrhea,
nausea and/or vomiting.
The nasal mucosa, pharyngeal wall, and the tonsil area
demonstrated mild hyperemia or an inflammatory reaction
with moisture on the mucous membrane in all of the cases
except the oropharynx of two cases (patients No. 4 and 5).
There was no lymphadenopathy in the nuchal areas, including
submental, submandibular, and upper, middle, or lower
cervical lymph nodes, in any of the cases. One case was found
to have redness of the eye (conjunctivitis). One case had
rhonchi in chest when auscultation was performed, but this
showed up as normal by chest radiography. One patient
showed abdominal tenderness, but no diarrhea was found
(Table 1).s
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¼In terms of our H1N1 cases, leukopenia (a white-cell
count of less than 5.0  103/mL) was found in nine cases
(64.2%), with a mean leukocyte count of 4.6  1.3
(range ¼ 3.0e8.21)  103/mL. Lymphopenia (a total lympho-
cyte count of less than 8.0  103/mL or less than 15%
lymphocytes in the total white-cell count) occurred in 35.7% of
cases, with a mean lymphocyte count of 1.0  0.4
(range ¼ 0.4e1.7)  103/mL. Thrombocytopenia (a total
Table 3
Logistic regression analysis relating to H1N1 reverse transcription polymerase
chain reaction positivity by associated variables using forward conditional
methods
Characteristics Adjusted OR 95% CI p
Age
>41 yr 1 0.624
31e40 yr 2.1 0.1e39.1 0.529
21e30 yr 2.5 0.1e45.3 0.034
0e20 yr 27.7 1.3e597.8
Traveling history
Others 1
US 14.5 2.1e101.4 0.007
Thailand 56.7 4.6e700.6 0.002
Symptoms
Myalgia (Y/N) 8.5 1.4e52.0 0.021
Leukopenia (Y/N) 17.4 3.4e90.5 0.001
Initial variables include: age, travel history, fever, myalgia, dizziness,
productive cough, diarrhea, conjunctivitis, and leukopenia.
CI ¼ confidence interval; N ¼ no; OR ¼ Odds ratio; US ¼ United States;
Y ¼ yes.
Table 2
Comparison between H1N1 influenza A (H1N1) infection cases and non-
H1N1 cases
Variables H1N1 (n ¼ 14)
No (%)
Non-H1N1 (n ¼ 152)
No (%)
p
Age
0e20 yr 6 (42.9) 17 (11.2) 0.021*
21e30 yr 5 (35.7) 57 (37.5)
31e40 yr 2 (14.3) 36 (23.7)
>41 1 (7.1) 42 (27.6)
Sex
Female 7 (50.0) 71 (46.7) 1.000
Male 7 (50.0) 81 (53.3)
Travel history
US 8 (57.1) 29 (19.1) <0.001*
Thailand 4 (28.6) 10 (6.6)
Others 2 (14.3) 113 (74.3)
Symptoms
Fever 13 (92.9) 105 (69.1) 0.069
Myalgia 8 (57.1) 41 (27.0) 0.029*
Productive cough 5 (35.7) 25 (16.4) 0.137
Conjunctivitis 1 (7.1) 1 (0.7) 0.164
Dizziness 0 (0.0) 20 (13.2) 0.223
Diarrhea 0 (0.0) 14 (9.2) 0.220
Infiltrate on
chest radiograph
0 (0.0) 16 (10.5) 0.365
Leukopeniaa 9 (64.3) 16 (10.5) <0.001*
Other variables included: contact history, chills, malaise, headache, sore
throat, rhinorrhea, nasal obstruction, sneezing, cough, nonproductive cough,
dyspnea, nausea and vomiting, abdominal tenderness, nose, throat, neck, lung,
lymphopenia, thrombocytopenia, and C-reactive protein. These variables
demonstrated no significant difference.
Statistics were obtained by Fisher’s exact test.
* A p value <0.05.
a Leukopenia was defined as a white-cell count of less than 5.0  103/mL.
No ¼ number.
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the patients having a mean thrombocyte count of 209.1  42.6
(range ¼ 154.0e313.0)  103/mL. The definitions of leuko-
penia, lymphopenia, and thrombocytopenia were the same as in
previous literature.11 The mean C-reactive protein was
6.5 6.8 (range¼ 0.0e21.0) mg/L. The patients’ renal function
tests, liver function tests, and chest radiographs were all normal.
The O2 saturation of these patients was measured during
quarantine. The lowest O2 saturation measured had a mean of
96.1  1.2% (range ¼ 95e98%). Viral shedding (from the first
day of illness to the day of the first negative PCR result of two
consecutively negative PCR tests) lasted a mean of 7.0  1.8
days.4.4. Treatment and outcomeAll patients including the children in our study were treated
with oseltamivir orally twice daily for 5 days using a dose
based on body weight according to the manufacturer’s
recommendations (for adults who were >40 kg, 75 mg twice
daily; for children who were: 15 kg, 30 mg twice daily;
>15e23 kg, 45 mg twice daily; >23e40 kg, 60 mg twice
daily; >40 kg, 75 mg twice daily). No patient requiredsupplemental oxygen or intubation. The lowest O2 saturation
for the H1N1 cases was not statistically different from that of
the non-H1N1 cases ( p ¼ 0.302). At the time of writing, all
14 patients had been discharged after a policy change by the
CDC, Taiwan on June 19, 2009, namely that there was no need
to isolate patients if there were no serious complications,12
since WHO considered H1N1 to be a moderate form of
influenza. The outcome was that all patients were discharged
from quarantine without mortality or morbidity.4.5. Risk indicators for being infected by novel H1N1
influenza virusAnalysis using Fisher’s exact test found that age, travel
history, myalgia and leukopenia were significantly different
between the H1N1 and non-H1N1 groups, as shown in Table 2.
Table 3 shows the risk indicators for H1N1 cases by logistic
regression analysis. A greater risk was found among the age
group younger than 20 years [Odds ration (OR) ¼ 27.7, 95%
confidence interval (CI) ¼ 1.3e597.8, p ¼ 0.034] and among
those who had traveled from the US (OR ¼ 14.5, 95%
CI ¼ 2.1e101.4, p ¼ 0.007) or Thailand (OR ¼ 56.7, 95%
CI ¼ 4.6e700.6, p ¼ 0.002). Patients presenting with myalgia
symptoms (OR ¼ 8.5, 95% CI ¼ 1.4e52.0, p ¼ 0.021) seemed
to have a greater risk of being infected with H1N1. Further-
more, initial laboratory findings of leukopenia (OR ¼ 17.4,
95% CI ¼ 3.4e90.5, p ¼ 0.001) were associated with a higher
risk of being infected with H1N1.
5. Discussion
To our knowledge, this is the first study comparing the
clinical and laboratory differences between H1N1 and
influenza-like non-novel H1N1 cases. We identified the char-
acteristics of H1N1 patients in the early phase of disease
spread. It has been shown that, in the community, the triad of
302 T.-H. Yang et al. / Journal of the Chinese Medical Association 74 (2011) 298e304fever, respiratory symptoms (cough, sore throat, or nasal
symptoms), and constitutional symptoms (headache, malaise,
myalgia, sweats/chills, or fatigue) has a sensitivity of 60%
if influenza was known to be present in the community.13
However, to guide isolation policy and therapy, a definitive
diagnosis of influenza as the causative organism is often
needed. RT-PCR is accurate; however, it is expensive, needs
4e24 hours,13,14 and is only available by means of a sophis-
ticated laboratory that can perform the procedure. When there
is a pandemic, the laboratory may not be able to tolerate the
testing load. The rapid influenza diagnosis test is a timely
method but relatively inaccurate, as it has a low sensitivity
(11.1e69%).15e17
In our study, 42.9% of H1N1 infected cases were 20 years
of age or less, in agreement with various previous series.1,18,19
Specifically, persons younger than 21 years have a higher odds
ratio of being infected by H1N1 virus. In a US school in New
York, all H1N1 cases were students, with the exception of one
student teacher aged 21 years20 The same phenomenon was
found in 1977, when Russian influenza mainly affected indi-
viduals aged 14e20 years. It is possible that the H1N1
circulating at present (a swine-origin triple-reassortant influ-
enza virus) has enough antigenic similarity to related H1N1
influenza strains of the past to allow older individuals exposed
to the virus to be protected if they had been infected
previously.21
Recent evidence suggests that transmission of influenza
occurs over short distances rather than over long distances and
occurs predominantly by the droplet and contact routes (within
3 feet), rather than by aerosol.13,22 Travel history to a highly
affected area, such as the US or Thailand, was strongly
correlated with H1N1 infection in our series ( p < 0.001).
Those who had traveled from Thailand had an odds ratio of
56.7 (95% CI ¼ 4.6e700.6) of being H1N1 infected, whereas
those who had traveled from the US had an odds ratio of 14.50
(95% CI ¼ 2.1e101.4) of being H1N1 infected. The airport
check point for fever identified a group of students who were
returning from Thailand on June 9, 2009 as having fever and
other symptoms. Three of them were confirmed to be victims
of the H1N1 novel virus infection after quarantine and
examination. Taiwan CDC reported this event to the WHO and
the Thailand government. Although Thailand was not cate-
gorized as an “at-risk” country during this early phase,
nevertheless confirmed cases of H1N1 from Thailand were
reported frequently during June, 2009 by Taiwan CDC.23
Moreover, the cumulative confirmed cases (518) from
Thailand were higher in number compared to other nearby
countries such as Philippines; the Republic of Korea; and
Malaysia as of June 19, 2009.24
Myalgia usually involves the long muscles of the back and
the extremities. Cytokines are responsible for the muscle ache.
Myalgia is present in 39% of influenza patients.25,26 Previous
H1N1 series have reported myalgia with a range from 30% to
59%.1,18,19,27,28 In our series, myalgia was found in 57.1% of
H1N1 cases and was the only significant symptom that
differentiated these cases from the non-H1N1 group. Logistic
regression showed it to be a predictor of H1N1 cases, with anodds ratio of 8.5 (95% CI ¼ 1.4e52.0). However, several
studies have found that symptoms and signs have a relatively
poor predictive value during an influenza outbreak.29e31 Monto
et al.32 reported that fever and cough occurred more frequently
among influenza patients involved in the clinical trials of one
antiviral agent, but these results may not apply directly to
a primary care setting because they represent pooled findings
across several epidemics. Fewer of our patients had a cough
(71.4%) or a sore throat (57.1%), rhinorrhea (coryza) (64.3%),
and none had diarrhea, compared to larger case series that
have been reported.1,18,19 However, none of the above symp-
toms show a statistically significant difference between the
H1N1 and non-H1N1 cases.
It is very unusual that, compared to other studies, none of
our cases reported gastrointestinal symptoms, such as diarrhea
(range ¼ 25e41%) and/or vomiting (range ¼ 13e25%).1,18,19
However, a series in Singapore also reported no diarrhea
among their first 10 cases.27 The information from People
Republic of China33 also showed that among their cases, only
2.8% have diarrhea and 1.9% had nausea and/or vomiting,
which was much lower than in other countries.
In our study, a patient with leukopenia had higher odds of
being a H1N1 case, with the mean leucocyte count for the
patients being 4.6  1.3  103/mL (range ¼ 3.0e8.2). Similar
findings have been found in other studies of influenza.30
Nonetheless, this is quite different from novel H1N1 cases
reported in Singapore, where there was a leucocytosis rate
of 30% and a mean leucocyte count of 7.8 (range
5.1e14.7)  103/mL.27 Although the etiology of leukopenia is
not known, it has been associated with a poor prognosis during
avian H5N1 infection.34 This blood test is not a routine test
that might be performed regularly outside of a hospital setting
overseas, but it can be easily and quickly obtained in Taiwan.
Our first patient had detectable virus in a nasopharyngeal
swab until Day 11 from their illness onset, after completion of
5 days of oseltamivir and the resolution of the fever and
respiratory symptoms. Two other patients still had detectable
virus in their nasopharyngeal swabs by RT-PCR on Days 7 and
8 of their illness, respectively. The mean duration of virus
shedding was found to be 7.0  1.8 days (Table 1). Although
the reported mean duration of viral shedding has been pre-
sented as 4.8 days in other studies of influenza, several studies
have reported viral shedding as late as Days 8e10 and
involving 20e30% of cases.35 A series of novel H1N1 infec-
tions reported from Singapore had findings similar to ours.27
Because this new virus has been shown to be sensitive to
oseltamivir,1 our observation that some patients had prolonged
viral shedding is intriguing. One possibility is that standard
viral culture detects “live virus” whereas the RT-PCR method
may not. Another possibility is that this may be due to a higher
false positive rate for the influenza RT-PCR assay compared
with viral culture,36 but it could also may suggest the possi-
bility of more prolonged viral shedding from this new influ-
enza A (H1N1). This could potentially result in longer
duration of infectivity and this possibility might aid the
emergence of oseltamivir resistance. There have been a total
of 313 cases of resistant H1N1 reported across the world up to
303T.-H. Yang et al. / Journal of the Chinese Medical Association 74 (2011) 298e304October 27, 2010.37 Monitoring for resistance to oseltamivir
started in July 2009 in Taiwan; however, no strains resistant to
oseltamivir were detected until two separate cases on Oct. 20,
2009 and Oct. 27, 2009 were identified.38 Furthermore, the
published meta-analysis of the duration of virus shedding35
has been mainly collected from studies where healthy volun-
teers had been inoculated, which is different from a naturally
acquired influenza virus infection. Further studies are
underway to delineate these concerns.
There are limitations that affect this hospital-based case
control study. Most important, although statistically significant
for both the Fisher’s exact test and logisitic regression, only 14
H1N1 cases were part of our study. Therefore, there may be
bias in estimating the prevalence of patient characteristics
because of the low numbers.
In conclusion, since novel H1N1 is pandemic at this time
and has been reported to have considerable mortality and
morbidity in Mexico, physicians dealing with patients who are
younger in age, have a history of travel to an affected area,
have myalgia, and have laboratory finding showing leukopenia
should take greater care with these individuals.Acknowledgments
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